B7-H3 Inhibitors in Oncology Clinical Trials: A Review
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Innovative Healthcare Institute
2024-02-01
|
| Edice: | Journal of Immunotherapy and Precision Oncology |
| Témata: | |
| On-line přístup: | https://jipo.org/doi/pdf/10.36401/JIPO-23-18 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|